
Open Your Free Demat Account
Enjoy low brokerage on delivery trades
BAJAJ BROKING
Biocon has received CDSCO approval for Liraglutide, a GLP-1 drug targeting Type 2 diabetes in individuals aged 10 and above. The launch will address a market with over 77 million Indian diabetics, expanding access to advanced treatment options.
Biocon Limited has gained regulatory approval in India for its diabetes treatment drug Liraglutide, marking a significant development in the country’s healthcare sector. The Central Drugs Standard Control Organisation (CDSCO) has cleared Biocon’s drug substance and its subsidiary Biocon Pharma’s drug product — a 6 mg/ml Liraglutide solution in pre-filled pens and cartridges — under the expedited 101 route.
Also read: Zinka Logistics Block Deal Launched; Quickroutes To Sell 9% Stake
Approval secured under CDSCO’s fast-track 101 route.
Liraglutide is the generic version of Novo Nordisk’s Victoza.
Indicated for Type 2 diabetes in adults and children aged 10+.
Biocon to launch the product via commercialisation partners.
Targets over 77 million diabetic patients in India.
Also read: Jindal Stainless Invests In 282 MW Hybrid Renewable Energy Project
The approval allows Biocon to tap into India’s growing diabetes care market, where an estimated 77 million people are currently living with the condition. Liraglutide belongs to the GLP-1 class of drugs, known for lowering blood glucose, aiding weight management, and slowing digestion to regulate insulin. The drug is approved for use alongside diet and exercise in treating Type 2 diabetes.
The CDSCO approval under the 101 route allows domestic companies to benefit from prior approvals by global regulators such as the US FDA and EMA. This regulatory framework aims to fast-track market entry of vital therapies and reduce the time required to bring essential generics to Indian patients.
Product | Strength | Form | Use | Regulatory Route |
Liraglutide (Generic Victoza) | 6 mg/ml | Pre-filled pens and cartridges | Type 2 diabetes treatment | CDSCO 101 route approval |
Biocon is preparing for the Indian launch through commercialisation partners, positioning itself to serve unmet needs in the diabetes segment. This step could help expand the footprint of cost-effective GLP-1 therapies in a country with rising lifestyle diseases.
Despite the regulatory milestone, Biocon share price closed marginally lower at Rs.333.75 on the BSE on the day of the announcement. The market may factor in longer-term prospects once the commercial rollout begins.
With India facing a growing diabetes burden, the introduction of Liraglutide adds a new tool in the fight against Type 2 diabetes. Biocon’s regulatory win not only underscores its strong pharmaceutical pipeline but also strengthens its role in chronic disease care. As the product enters the market, attention will remain on commercial execution and its impact on the Biocon share price in the coming quarters.
Also read: Adani Group Faces US Scrutiny Over Alleged Iranian LPG Shipments
Source: CNBCTV18
Share this article:
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading